The controlled release of vancomycin in gelatin/β-TCP composite scaffolds.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22499502.
- Also identified by DOI 10.1002/jbm.a.34170.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Osteomyelitis remains a difficult infection to treat for orthopaedic surgeons regardless of the continuous advances in surgical techniques and antimicrobial agents. The controlled release of vancomycin from local delivery system is a promising method for eliminating infection. In this study, biodegradable gelatin sponge containing different contents of β-tricalcium phosphate ceramic (β-TCP) was prepared for the controlled-release of vancomycin. We aimed to confirm the composite scaffolds could be used as a vancomycin sustained-release system. Examinations of scanning electron microscopy, Fourier transform infrared spectroscopy, mechanical properties, and in vivo drug release were performed. The results showed that the composite scaffolds could achieve local therapeutic drug levels over an extended duration. Taking consideration of porosity, interconnection, mechanical properties, and controlled release performance, the composite gelatin scaffold containing 30% β-TCP granules may be a good candidate for the controlled release of vancomycin in the treatment of chronic osteomyelitis.
Medical subject headings
- Anti-Bacterial Agents
- Calcium Phosphates
- Delayed-Action Preparations
- Gelatin
- Tissue Scaffolds
- Vancomycin